Cargando…

Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients

PURPOSE/METHODS: The determination of tumour biomarkers is paramount to advancing personalized medicine, more so in rare tumours like medullary thyroid carcinoma (MTC), whose diagnosis is still challenging. The aim of this study was to identify non-invasive circulating biomarkers in MTC. To achieve...

Descripción completa

Detalles Bibliográficos
Autores principales: Besharat, Z. M., Trocchianesi, S., Verrienti, A., Ciampi, R., Cantara, S., Romei, C., Sabato, C., Noviello, T. M. R., Po, A., Citarella, A., Caruso, F. P., Panariello, I., Gianno, F., Carpino, G., Gaudio, E., Chiacchiarini, M., Masuelli, L., Sponziello, M., Pecce, V., Ramone, T., Maino, F., Dotta, F., Ceccarelli, M., Pezzullo, L., Durante, C., Castagna, M. G., Elisei, R., Ferretti, E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632281/
https://www.ncbi.nlm.nih.gov/pubmed/37286863
http://dx.doi.org/10.1007/s40618-023-02115-2
_version_ 1785146130868207616
author Besharat, Z. M.
Trocchianesi, S.
Verrienti, A.
Ciampi, R.
Cantara, S.
Romei, C.
Sabato, C.
Noviello, T. M. R.
Po, A.
Citarella, A.
Caruso, F. P.
Panariello, I.
Gianno, F.
Carpino, G.
Gaudio, E.
Chiacchiarini, M.
Masuelli, L.
Sponziello, M.
Pecce, V.
Ramone, T.
Maino, F.
Dotta, F.
Ceccarelli, M.
Pezzullo, L.
Durante, C.
Castagna, M. G.
Elisei, R.
Ferretti, E.
author_facet Besharat, Z. M.
Trocchianesi, S.
Verrienti, A.
Ciampi, R.
Cantara, S.
Romei, C.
Sabato, C.
Noviello, T. M. R.
Po, A.
Citarella, A.
Caruso, F. P.
Panariello, I.
Gianno, F.
Carpino, G.
Gaudio, E.
Chiacchiarini, M.
Masuelli, L.
Sponziello, M.
Pecce, V.
Ramone, T.
Maino, F.
Dotta, F.
Ceccarelli, M.
Pezzullo, L.
Durante, C.
Castagna, M. G.
Elisei, R.
Ferretti, E.
author_sort Besharat, Z. M.
collection PubMed
description PURPOSE/METHODS: The determination of tumour biomarkers is paramount to advancing personalized medicine, more so in rare tumours like medullary thyroid carcinoma (MTC), whose diagnosis is still challenging. The aim of this study was to identify non-invasive circulating biomarkers in MTC. To achieve this goal, paired MTC tissue and plasma extracellular vesicle samples were collected from multiple centres and microRNA (miRNA) expression levels were evaluated. RESULTS: The samples from a discovery cohort of 23 MTC patients were analysed using miRNA arrays. Lasso logistic regression analysis resulted in the identification of a set of circulating miRNAs as diagnostic biomarkers. Among them, miR-26b-5p and miR-451a, were highly expressed and their expression decreased during follow-up in disease-free patients in the discovery cohort. Circulating miR-26b-5p and miR-451a were validated using droplet digital PCR in a second independent cohort of 12 MTC patients. CONCLUSION: This study allowed the identification and validation of a signature of two circulating miRNAs, miR-26b-5p and miR-451a, in two independent cohorts reporting a significant diagnostic performance for MTC. The results of this study offer advancements in molecular diagnosis of MTC proposing a novel non-invasive tool to use in precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-023-02115-2.
format Online
Article
Text
id pubmed-10632281
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106322812023-11-14 Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients Besharat, Z. M. Trocchianesi, S. Verrienti, A. Ciampi, R. Cantara, S. Romei, C. Sabato, C. Noviello, T. M. R. Po, A. Citarella, A. Caruso, F. P. Panariello, I. Gianno, F. Carpino, G. Gaudio, E. Chiacchiarini, M. Masuelli, L. Sponziello, M. Pecce, V. Ramone, T. Maino, F. Dotta, F. Ceccarelli, M. Pezzullo, L. Durante, C. Castagna, M. G. Elisei, R. Ferretti, E. J Endocrinol Invest Original Article PURPOSE/METHODS: The determination of tumour biomarkers is paramount to advancing personalized medicine, more so in rare tumours like medullary thyroid carcinoma (MTC), whose diagnosis is still challenging. The aim of this study was to identify non-invasive circulating biomarkers in MTC. To achieve this goal, paired MTC tissue and plasma extracellular vesicle samples were collected from multiple centres and microRNA (miRNA) expression levels were evaluated. RESULTS: The samples from a discovery cohort of 23 MTC patients were analysed using miRNA arrays. Lasso logistic regression analysis resulted in the identification of a set of circulating miRNAs as diagnostic biomarkers. Among them, miR-26b-5p and miR-451a, were highly expressed and their expression decreased during follow-up in disease-free patients in the discovery cohort. Circulating miR-26b-5p and miR-451a were validated using droplet digital PCR in a second independent cohort of 12 MTC patients. CONCLUSION: This study allowed the identification and validation of a signature of two circulating miRNAs, miR-26b-5p and miR-451a, in two independent cohorts reporting a significant diagnostic performance for MTC. The results of this study offer advancements in molecular diagnosis of MTC proposing a novel non-invasive tool to use in precision medicine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-023-02115-2. Springer International Publishing 2023-06-07 2023 /pmc/articles/PMC10632281/ /pubmed/37286863 http://dx.doi.org/10.1007/s40618-023-02115-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Besharat, Z. M.
Trocchianesi, S.
Verrienti, A.
Ciampi, R.
Cantara, S.
Romei, C.
Sabato, C.
Noviello, T. M. R.
Po, A.
Citarella, A.
Caruso, F. P.
Panariello, I.
Gianno, F.
Carpino, G.
Gaudio, E.
Chiacchiarini, M.
Masuelli, L.
Sponziello, M.
Pecce, V.
Ramone, T.
Maino, F.
Dotta, F.
Ceccarelli, M.
Pezzullo, L.
Durante, C.
Castagna, M. G.
Elisei, R.
Ferretti, E.
Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
title Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
title_full Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
title_fullStr Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
title_full_unstemmed Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
title_short Circulating miR-26b-5p and miR-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
title_sort circulating mir-26b-5p and mir-451a as diagnostic biomarkers in medullary thyroid carcinoma patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10632281/
https://www.ncbi.nlm.nih.gov/pubmed/37286863
http://dx.doi.org/10.1007/s40618-023-02115-2
work_keys_str_mv AT besharatzm circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT trocchianesis circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT verrientia circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT ciampir circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT cantaras circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT romeic circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT sabatoc circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT noviellotmr circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT poa circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT citarellaa circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT carusofp circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT panarielloi circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT giannof circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT carpinog circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT gaudioe circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT chiacchiarinim circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT masuellil circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT sponziellom circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT peccev circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT ramonet circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT mainof circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT dottaf circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT ceccarellim circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT pezzullol circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT durantec circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT castagnamg circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT eliseir circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients
AT ferrettie circulatingmir26b5pandmir451aasdiagnosticbiomarkersinmedullarythyroidcarcinomapatients